Dina Halegoua de Marzio, MD
Gastroenterology · Philadelphia, PANPI 1235347105
Payments from drug & device makers
Across 527 payments — averaging $2915.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$610K
- E.r. Squibb & Sons, L.L.C.$349K
- Gilead$186K
- Madrigal Pharmaceuticals$166K
- Novo Nordisk AS$63K
- Pfizer$58K
- plus $104K from 10 others
Across 4 payments — averaging $1414.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$4K
- E.r. Squibb & Sons, L.L.C.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 102 | $609,726 |
| E.r. Squibb & Sons, L.L.C. | 15 | $349,381 |
| Gilead | 44 | $186,172 |
| Madrigal Pharmaceuticals | 68 | $166,439 |
| Novo Nordisk AS | 217 | $63,228 |
| Pfizer | 9 | $57,902 |
| Intercept Pharma Europe Ltd. | 5 | $56,287 |
| Tanabe Pharma America, Inc. | 47 | $28,524 |
| Vertex | 8 | $8,775 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $3,000 |
| Novo Nordisk | 2 | $2,745 |
| Mallinckrodt Hospital Products Inc. | 2 | $2,223 |
| Bausch Health US, LLC | 1 | $1,463 |
| Merck | 1 | $500 |
| GSK | 1 | $59 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
How this compares
$1,536,474 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
- Michael KochmanPhiladelphia$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.